Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANONASDAQ:KNBENASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANOCano Health$3.81$1.74▼$190.00$12.39M0.05423,785 shs159,142 shsKNBEKnowBe4$24.89$24.85$13.78▼$26.00$4.35B0.321.34 million shsN/ASAVACassava Sciences$1.27-8.6%$2.39$1.25▼$42.20$67.15M-1.482.96 million shs1.41 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANOCano Health0.00%0.00%0.00%0.00%0.00%KNBEKnowBe40.00%0.00%0.00%0.00%0.00%SAVACassava Sciences-8.63%-25.29%-52.61%-56.06%-93.83%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANOCano HealthN/AN/AN/AN/AN/AN/AN/AN/AKNBEKnowBe4N/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.8418 of 5 stars3.33.00.04.71.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANOCano Health 0.00N/AN/AN/AKNBEKnowBe4 0.00N/AN/AN/ASAVACassava Sciences 2.50Moderate Buy$54.504,191.34% UpsideCurrent Analyst Ratings BreakdownLatest CANO, KNBE, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANOCano Health$2.74B0.00N/A0.03$100.28 per share0.00KNBEKnowBe4$246.30M17.65$0.26 per share94.66$1.25 per share19.91SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANOCano Health-$207.27M-$215.87N/AN/AN/A-18.62%-133.59%-19.18%N/AKNBEKnowBe4-$11.85M$0.10248.90311.136.215.02%11.31%4.46%N/ASAVACassava Sciences-$97.22M-$1.45N/AN/AN/AN/A-88.05%-64.98%5/9/2025 (Estimated)Latest CANO, KNBE, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANOCano HealthN/AN/AN/AN/AN/AKNBEKnowBe4N/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANOCano Health3.950.400.40KNBEKnowBe4N/A1.621.62SAVACassava SciencesN/A3.553.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANOCano Health35.99%KNBEKnowBe491.90%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCANOCano Health13.93%KNBEKnowBe45.03%SAVACassava Sciences9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANOCano Health4,3655.41 million4.65 millionOptionableKNBEKnowBe41,366174.70 million165.91 millionNot OptionableSAVACassava Sciences3048.31 million43.78 millionOptionableCANO, KNBE, and SAVA HeadlinesRecent News About These CompaniesShort Interest in Cassava Sciences, Inc. (NASDAQ:SAVA) Declines By 17.8%April 3 at 12:58 PM | marketbeat.comDown -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a TurnaroundApril 1 at 10:35 AM | zacks.comIs the Future Bleak for SAVA Stock Following Another Setback?March 31, 2025 | zacks.comNotable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focusMarch 30, 2025 | msn.comCassava Sciences must face malicious prosecution lawsuit over Alzheimer's drugMarch 26, 2025 | reuters.comHC Wainwright Reiterates Neutral Rating for Cassava Sciences (NASDAQ:SAVA)March 26, 2025 | marketbeat.comEnd of the line for Cassava's troubled Alzheimer's programmeMarch 26, 2025 | pharmaphorum.comCassava ends simufilam Alzheimer’s programme after second Phase III failureMarch 26, 2025 | finance.yahoo.comSAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyMarch 26, 2025 | zacks.comCassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpointMarch 26, 2025 | markets.businessinsider.comCassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’sMarch 26, 2025 | markets.businessinsider.comCassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains HopefulMarch 26, 2025 | msn.comCassava to phase out Alzheimer’s program by Q2March 25, 2025 | msn.comWhy Cassava Sciences, Inc.’s (SAVA) Stock Is Down 20.00%March 25, 2025 | aaii.comCassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be DiscontinuedMarch 25, 2025 | marketwatch.comCassava Finally Ends Alzheimer’s Program for Embattled SimufilamMarch 25, 2025 | biospace.comCassava stops Alzheimer's program as simufilam fails another phase 3March 25, 2025 | fiercebiotech.comCassava to discontinue development of Alzheimer's disease drugMarch 25, 2025 | msn.comCassava Sciences' controversial Alzheimer's drug fails in second late-stage studyMarch 25, 2025 | msn.comCassava Sciences Reports Topline Phase 3 REFOCUS-ALZ DataMarch 25, 2025 | globenewswire.comAfrica’s AI Revolution Begins: Cassava Technologies Launches AI Factory with NVIDIAMarch 24, 2025 | devdiscourse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANO, KNBE, and SAVA Company DescriptionsCano Health NYSE:CANOCano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.KnowBe4 NASDAQ:KNBEKnowBe4, Inc. engages in the development, marketing, and sale of its Software-as-a-Service-based security awareness platform. The company provides a platform incorporating security awareness training and simulated phishing with analytics and reporting that helps organizations manage the ongoing problem of social engineering. Its products include Kevin Mitnick Security Awareness Training, a security awareness training product; Compliance Plus, a compliance training product, which enables organizations to offer their employees with relevant, timely, and engaging compliance content across a range of topics from data privacy to diversity, equity, and inclusion; PhishER, its security orchestration, automation, and response product, which enables security professionals to prioritize and automate security workstreams in response to attacks targeted at the human layer; and KnowBe4 Compliance Manager, its governance, risk, and compliance product that enables organizations to analyze security risk and automate the management of compliance and audit functions. The company also offers Security Coach, a solution to address human behavior risks through human detection and response; and PasswordIQ that would be used to mitigate risk related to password hygiene issues, such as weak or breached passwords. It serves its customers directly through inside sales teams for enterprise and small and medium businesses, as well as indirectly through channel partners and managed service providers. The company was formerly known as SEQRIT, LLC and changed its name to KnowBe4, Inc. in January 2016. KnowBe4, Inc. was founded in 2010 and is headquartered in Clearwater, Florida.Cassava Sciences NASDAQ:SAVA$1.27 -0.12 (-8.63%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.57%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
